A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Background: This phase II study estimated the difference in objective response rate (ORR) among patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) receiving paclitaxel-carboplatin (CP) plus motesanib or bevacizumab.
著者Blumenschein GR, Kabbinavar F, Menon H, Mok TSK, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L
期刊名稱Annals of Oncology
出版年份2011
月份9
日期1
卷號22
期次9
出版社Oxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
頁次2057 - 2067
國際標準期刊號0923-7534
電子國際標準期刊號1569-8041
語言英式英語
關鍵詞bevacizumab; motesanib; nonsquamous non-small-cell lung cancer; objective response rate; pharmacokinetics
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2020-24-10 於 01:33